The three largest pharmacy benefit managers (PBMs) are unflinching in the face of a new Federal Trade Commission interim report Tuesday outlining the intricacies of the US healthcare system — and blaming PBMs for higher drug prices. "Their outsized influence comes not only from the expansion of their traditional, middlemen administrative services in processing patients’ pharmacy prescription claims, but also from decades of consolidation and vertical integration across the healthcare delivery system," said FTC Chair Lina Khan in the 73-page report. Per the FTC, in 2000 there were more than two dozen independent players in the PBM market. By 2021, only the current "Big Three" remained: CVS's (CVS) Caremark, UnitedHealth Group's (UNH) Optum Rx, and Cigna's (CI) Express Scripts. Shares of all three were unaffected by the report. In the report, the FTC highlighted that the top three PBMs processed nearly 80% of about 6.6 billion prescriptions dispensed by US pharmacies in 2023. And PBM revenues have increased as a percentage of national spend, jumping from 14% in 2016, or $456 billion, to 22%, or more than $1 trillion, in 2023. "Today, if the Big 3 PBMs were standalone companies, each would rank among the 40 largest companies in the United States by revenue," according to the report. "Given the current level of consolidation, pharmacists, health insurers, and drug manufacturers often have little choice but to interact with the large, dominant PBMs when distributing certain drugs," the FTC said. Lina Khan, Chair of the Federal Trade Commission. (Kevin Dietsch/Getty Images) (Kevin Dietsch via Getty Images) No action The companies, no surprise, weren't keen on the idea of future regulation. "Any suggestions from the FTC about policies that limit the use of PBM negotiating tools would instead reward the pharmaceutical industry, leaving American businesses and patients at the mercy of the prices drugmakers set," CVS said in a statement to Yahoo Finance. Cigna, meanwhile, said the company had cooperated with the FTC's requests and provided millions of documents. "These biased conclusions will do nothing to address the rising prices of prescription medications ... we look forward to addressing the blatant inaccuracies in the Commission’s initial report," Cigna said, also in a statement to Yahoo Finance. Navitus, a PBM owned by Catholic nonprofit health system SSM Health and Costco (COST), is just one of many smaller PBMs hoping to fight the status quo. CEO David Fields compared the "Big Three" to Big Tobacco in terms of the harm done to the American public. "Much like Big Tobacco, these PBMs will continue their harmful practices until they are forced to change. Reform is urgently needed to ensure ALL PBMs prioritize patient health and affordability in their practices, and to build trust again with a more transparent and accountable healthcare system," Fields told Yahoo Finance in a statement. Analysts also weighed in. JPMorgan's Lisa Gill said in a note to clients that the report's findings "fall short of any charges against the PBMs." She also added that the report doesn't offer any empirical evidence linking PBM consolidation and higher drug prices. Her comments echo the dissenting statement from one of the FTC's commissioners, Melissa Holyoak, who said that the report "was plagued by process irregularities and ... leaves us without a better understanding of the competition concerns surrounding PBMs or how consumers are impacted by PBM practices." Prior to her time at the FTC, Holyoak was Utah Solicitor General and was involved in the state's efforts to file suit against Eli Lilly (LLY), Novo Nordisk (NVO), and Sanofi (SNY) for allegedly inflating the price of insulin. "To assert that market conditions have changed is one thing—but to ignore the 2005 Report without conducting a new empirical analysis of market conditions or explaining why the findings, conclusions, and empirical work no longer apply is a different matter entirely," Holyoak said. The 2005 report was a look at the industry that concluded that the PBM environment was competitive — but at a time when there were still more than two dozen PBMs in the market. In its final report, the FTC is looking to provide an update, reflecting the transformation the market has undergone in the past 20 years. The agency did not include any recommendations for antitrust law enforcement in the interim report, but noted that "PBM and brand pharmaceutical rebating practices ... urgently warrant further scrutiny and potential regulation." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. Follow Anjalee on all social media platforms @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Read the latest financial and business news from Yahoo Finance
FTC Chair Khan slams PBMs for higher drug prices in an interim report on the industry
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...